LONDON: The fallout over the AstraZeneca jab persisted Thursday with several countries halting its use among younger people, as nations raced to secure much-needed vaccines in the face of fresh virus surges.
Europe’s medicines regulator said this week the AstraZenea vaccine could cause very rare blood clots among some recipients, prompting a cascade of countries to pull the plug on giving it to people under a certain age.
Britain sought Thursday to quell fears over the jab, saying the potential side effects were extremely rare — and the risk of getting seriously sick from Covid-19 was far greater. The furore over the jab comes as a number of countries battle mounting caseloads and deaths, more than a year into the pandemic that has killed almost 2.9 million people worldwide and ravaged the global economy.
Australia and the Philippines became the latest countries to restrict the use of AstraZeneca to older populations, joining several others, including Spain, Italy, France, Germany and Canada that took the decision earlier.
“It has not been our practice to jump at shadows, it has not been our practice to take unnecessary precautions,” Australian Prime Minister Scott Morrison said in announcing the measure. “We’ve been taking the necessary precautions based on the best possible medical advice.”
The decision came after the European Medicines Agency said Wednesday that blood clots should be listed as a “very rare” side effect of the jab, though it did not say any particular groups were at greater risk. Britain said it would offer people under 30 “alternative” vaccines to AstraZeneca — the country has also approved Pfizer and Moderna jabs — but on Thursday sought to reassure people about getting inoculated. “The vaccines are safe, and if you want to have the Pfizer vaccine or Moderna vaccine instead then that is fine,” Health Secretary Matt Hancock told the BBC. “Covid is a horrible disease and long Covid affects people in their 20s just as much it seems as any other age group and can have debilitating side effects that essentially ruin your life.”
AstraZeneca has been dogged by controversy since it was rolled out — first banned by some governments for older people over lack of data, then banned outright over clot fears. It is stored at a warmer temperature and billed as the vaccine of choice for poorer countries since it can be transported more readily than some of its counterparts. It has already been administered in some 111 countries — more than its competitors Pfizer/BioNTech and Moderna put together — according to an AFP database from official sources.
The Covax programme, which provides vaccine doses to poorer countries, was unequivocal.
More than 700 million people across India were facing coronavirus vaccine shortages after stocks dried up, even as the country saw a record 126,000 new infections in the past 24 hours.
And Indonesia said the delivery of over 100 million AstraZeneca doses could be delayed because of export restrictions in India — which produces the jab — and company supply holdups.